PhRMA

01/22/2026

Middlemen exercise significant control over:

👉What medicines you can get
👉What you pay at the pharmacy counter
👉What pharmacy you can use
👉What hoops you jump through to get the medicine your doctor prescribed

America’s patients deserve better. Washington must hold PBMs and insurers accountable.

https://phrma.org/blog/can-t-get-your-medicine-don-t-count-on-your-insurer

01/22/2026

The reality is spending on medicines is padding the profits of middlemen, often at the expense of patients.

PBMs and insurers get billions in rebates on medicines that can reduce the cost of brand medicines by 50% or more. Yet, they often fail to pass those savings directly to patients.

As a result, patients can pay more for medicines than middlemen.

It’s time to pass savings on to patients and hold middlemen like PBMs and insurers accountable.

https://phrma.org/blog/can-t-get-your-medicine-don-t-count-on-your-insurer

01/22/2026

Half of every dollar spent on brand medicines goes to entities who don’t make them. 💰

Even when PBMs get billions of dollars in rebates and discounts that can reduce the cost of brand medicines by 50% or more, they’re making patients pay the full price.

For too long, PBMs and insurers have been driving up costs for patients. Learn how we can hold these middlemen accountable:

https://www.phrma.org/policy-issues/pbms-middlemen

01/21/2026

The top three PBMs, which process nearly 80% of prescriptions in the United States, are now part of the same company as the three largest health insurers creating mega health care conglomerates.

This consolidation gives these companies immense market power and significant ability to increase patient costs. PBMs and insurers can steer patients to the pharmacies they own at the expense of patients and the government, drawing extensive investigation by the FTC and Congress.

Stop PBMs and insurers from driving up costs for patients:

https://phrma.org/blog/can-t-get-your-medicine-don-t-count-on-your-insurer

01/20/2026

PhRMA is happy to welcome Stemline as a new member.

Stemline is a biopharmaceutical company focused on developing and commercializing transformational novel oncology therapies—treatments that aim to improve outcomes for people living with cancer.

Our first new member of 2026, they join a growing list of PhRMA member companies committed to strengthening U.S. biopharmaceutical leadership in this pivotal time.

https://phrma.org/resources/phrma-welcomes-stemline-therapeutics-as-newest-member

01/17/2026

The 340B program has quietly grown to $81.4 billion as of 2024, according to new data from Health Resources and Services Administration (HRSAgov)—making it the second-largest federal drug program, with spending up more than 20% year over year.

The program costs taxpayers billions and government agencies have found no evidence that patients are benefitting.

Increased 340B spending isn’t improving patient access or affordability.

It’s time to take action to prevent waste, fraud and abuse in the health care system—and fix the 340B program so it works for patients.

https://phrma.org/blog/340b-s-billion-dollar-boom-oversight-lags-as-spending-soars

01/16/2026

Insurers and their PBMs have consolidated enormous power, creating mega-companies that influence the quality of patient care. They can steer patients, delay treatment and add hurdles that block access to care.

Here are 3 things to know:

1. Insurer–PBM vertical integration can increase patient costs.

2. Middlemen increasingly control what medicines patients can access, what they pay and where they can fill prescriptions.

3. In the U.S., about half of every dollar spent on brand medicines goes to entities that don’t make the medicines.

Washington has an opportunity to put Americans first and stop PBMs and insurers from driving up drug costs and blocking access to life-saving medicines.

https://phrma.org/blog/can-t-get-your-medicine-don-t-count-on-your-insurer

01/15/2026

America’s childhood vaccine schedule should protect our kids—not put them at risk.
Recent changes were made without scientific justification, weakening recommendations for vaccines that prevent serious illnesses like rotavirus, influenza and RSV. This action risks reversing decades of progress and increasing preventable illness, hospitalizations and child mortality.

Our vaccine schedule must reflect U.S. epidemiology, health system realities and robust, evidence‑based review.

Read more in our new blog:

01/14/2026

There are plenty of myths floating around about ADHD medications, but did you know that 80% of children with ADHD see symptoms improve with the right stimulant medication and dose?

Hear from Dr. Mike Ybarra and get the facts about ADHD meds:

http://phrma.org/mentalhealth

01/13/2026

In yet another major milestone for American drug discovery, Eli Lilly has announced their new AI co-innovation lab in collaboration with NVIDIA. Their joint investment of $1 billion over the next five years will help to accelerate medicine development through new infrastructure, expert talent and advanced computing technologies.

With cutting edge partnerships like these, our industry is committed to supporting American innovation and improving patient outcomes.

Read more about the collaboration working to discover the cures of tomorrow:

https://investor.lilly.com/news-releases/news-release-details/nvidia-and-lilly-announce-co-innovation-ai-lab-reinvent-drug?fbclid=IwY2xjawPTfEJleHRuA2FlbQIxMQBicmlkETFLRUhWQXU3Z2V2a1Nvellsc3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHu86JWhzzwa4KFGrzJ_pWAOkiaSIhfeCqYPoyClnrclMCrD0snAkYqOchfbt_aem_YaaCutL0_-5RC-l6FQS1Wg

01/12/2026

Novartis’ new radioligand therapy (RLT) manufacturing facility in Florida highlights our industry’s commitment to investing in American communities.

Learn more about how this milestone investment is delivering treatment to patients with the speed and reliability they deserve:

New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern USPurpose-built facility will strengthen Novartis RLT manufacturing network alongside existing Indiana, New Jersey, and recently completed California sites